Facebook
X
LinkedIn
Forward
ASTRO/ILROG Joint Activity: The Comeback of RT – Radiation Therapy is Back in the Frontline of Managing Hodgkin and Indolent Lymphomas
Given the rarity of lymphomas, many clinicians are not using radiation therapy appropriately in the frontline setting. Even when it is used, the clinician may not have had adequate experience in treating lymphomas, as a paltry 8 cases are required to meet minimum competency during residency training. As a result, educational sessions such as these are a critical way for clinicians to stay up to date on literature as well as learn new and emerging ways to treat lymphomas with radiation therapy.
In the past decade, the role of radiation therapy in lymphomas has shifted significantly. While initially there appeared to be data supporting a decreased need for RT in the frontline settings for non-Hodgkin and Hodgkin lymphomas, recent data showing unforeseen toxicities from chemotherapy, as well as changing approaches to using radiation therapy in lymphomas have solidified that radiation therapy is more important than ever in the frontline setting.
Topics:
- Updated and Recent Studies that Established the Necessity of RT in Early-Stage Hodgkin Lymphoma
George Mikhaeel, MD, MBBS - When, How and Why Should We Use Very Low Dose RT in Indolent Lymphomas?
Brandon S. Imber, MD, MS - Short and Long-Term Chemotherapy Toxicity Concerns in Lymphomas
Joanna C. Yang, MD, MPH - Closing Comments
Joachim Yahalom, MD, FASTRO
This activity is available from June 9, 2026, through 11:59 p.m. Eastern time on June 8, 2028.
The content was originally presented and recorded at the 2025 ASTRO Annual Meeting.
Target Audience
The activity is designed to meet the interests of medical oncologists, radiation oncologists, nurses and residents.
Learning Objectives
Upon completion of this activity, participants should be able to:
- Describe short and long-term toxicities of chemotherapies used to treat common lymphomas, including secondary malignancies.
- Discuss new studies on how to best use radiation therapy in the frontline setting for Hodgkin lymphoma and indolent NHL.
Moderator:
- Joachim Yahalom, MD, FASTRO is employed by Memorial Sloan Kettering Cancer Center. Dr. Yahalom has no relevant financial relationship with ineligible companies to disclose.
Speakers:
- George Mikhaeel, MD, MBBS, is employed by Guy’s Cancer Centre, Guy’s and St. Thomas NHS Foundation Trust. Dr. Mikhaeel has no relevant financial relationship with ineligible companies to disclose.
- Brandon S. Imber, MD, MS, is employed by Memorial Sloan Kettering Cancer Center. Dr. Imber receives grant/research funding from AstraZeneca, Bayer, Kazia Therapeutics and Novartis. Dr. Imber receives honoraria from GT Medical Technologies.
- Joanna C. Yang, MD, MPH, is employed by Washington University in St. Louis. Dr. Yang has no relevant financial relationship with ineligible companies to disclose.
Planners:
- Malcolm Mattes, MD, is employed at Rutgers Cancer Institute. Dr. Mattes received research/grant funding from Gilead Sciences (relationship ended 8/30/2025). Dr. Mattes has no relevant financial relationship with ineligible companies.
- Parul Barry, MD, is employed by the University of Pittsburgh Medical Center. Dr. Barry has no relevant financial relationship with ineligible companies.
- Michael Haddock, MD, is employed by Mayo Clinic and has no relevant financial relationship with ineligible companies to disclose.
- Manisha Palta, MD, is employed by Duke Cancer Center and Duke University Hospital. Dr. Palta receives grant/research funding from Merck and Varian Medical Systems.
- Salma Jabbour, MD, is employed by Rutgers Cancer Institute. Dr. Jabbour receives grant/research funding from Merck & Co., Inc. and Beigene. Dr. Jabbour receives compensation/payment as a consultant with Radialogica and IMX Medical.
All relevant financial relationships have been mitigated.
The American Society for Radiation Oncology (ASTRO) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
Available Credit
- 1.00 AMA PRA Category 1 Credit™
The American Society for Radiation Oncology (ASTRO) is accredited by the Accreditation Council for Continuing Medical Education for physicians. ASTRO designates this Enduring material for a maximum of 1.00 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
- 1.00 Certificate of AttendanceThis activity was designated for 1.00 AMA PRA Category 1 Credit™.
Price
Course Fees:
ASTRO members must log in to the ASTRO website to view and receive the member rate.
- Nonmember: $149
- Member: $99
- Member-in-Training: $49
- Student/Graduate Student/PGY-1 Member: $49
- Postdoctoral Fellow Member: $49
If you are an ASTRO member from a low or lower-middle income country, as identified by the World Bank, you can receive a 50% discount off your corresponding registration for this activity. Please email [email protected] to inquire about the discount.
Policies:
No refunds, extensions, or substitutions will be made for those participants who, for any reason, have not completed the activity by the expiration date.
Participants using ASTRO Academy activities to satisfy the requirement of a Continuing Certification (MOC) program should verify the credit number and type and availability dates of any activity before making a purchase. No refunds, extensions, or substitutions will be made for participants who have purchased activities that do not align with their MOC requirement.
The activity and its materials will only be available on the ASTRO website until June 8, 2028, regardless of purchase date. At the expiration of the activity, participants will no longer have access to the activity or its materials. ASTRO reserves the right to remove an activity before its expiration date.
Required Hardware/software
One of the two latest versions of Google Chrome, Mozilla Firefox, Internet Explorer or Safari.